O. Tembo

Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab

M.E. Dujaric, Véronique Scott, O. Tembo et al. · British Journal of Cancer · 2013 · 92 citations · Full text

Medicine, Molecular Medicine, Oncology +16

BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy

Anne‐Sophie Hamy, Ivan Bièche, Véronique Scott et al. · Breast Cancer Research and Treatment · 2016 · 57 citations

Medicine, Cancer Biology, Oncology +14

Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status

Sylvie Giacchetti, Anne‐Sophie Hamy, Suzette Delaloge et al. · European Journal of Cancer · 2017 · 26 citations

Medicine, Oncology, Pharmacotherapy +17

Single Circulating Tumor Cell Detection and Overall Survival in Non Metastatic Breast Cancer.

F-C Bidard, Claire Mathiot, F. Mefti et al. · Cancer Research · 2009 · 20 citations

Medicine, Clinical Sciences, Oncology +17

Challenging single- and multi-probesets gene expression signatures of pathological complete response to neoadjuvant chemotherapy in breast cancer: Experience of the REMAGUS 02 phase II trial

Fabien Valet, Patricia de Crémoux, F. Spyratos et al. · The Breast · 2013 · 13 citations

Medicine, Genetics, Oncology +13